Welcome, Guest. Please login or register.
June 12, 2024, 02:41:38 pm

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55127
  • Total Topics: 4851
  • Online Today: 141
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 144
Total: 144


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: NASH Next for Drug Makers After Hepatitis C Successes  (Read 10271 times)

0 Members and 1 Guest are viewing this topic.

Offline iana5252

  • Administrator
  • Member
  • Posts: 187
NASH Next for Drug Makers After Hepatitis C Successes
« on: May 07, 2015, 09:30:29 am »
The American Liver Foundation (ALF) predicts obesity-related fatty liver diseases such as nonalcoholic steatohepatitis (NASH) could affect as many as half of all Americans by 2030. ALF estimates that NASH already affects up to 30 percent of the U.S. population. NASH has no cure; doctors can only recommend patients lose weight.

New drugs could help address the advanced fibrosis and cirrhosis caused by HBV and NASH. The treatments may also be able to prevent liver cancer. If successful, the drugs could bring in as much as $10 billion annually once they’re approved.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.